The subgroup analysis of primary PTCs showed a relatively higher cumulative prevalence of RAIR in mutant BRAF patients compared to wild-type BRAF patients, but this did not reach statistical significance (OR = 2.45, P = 0.12, Figure 5A ).
← all excerpts
The effect of <i>BRAF<sup>V600E</sup></i> mutation on radioiodine therapy in patients with papillary thyroid carcinoma: a meta-analysis and systematic review.
1
0.1200
0.1200